Dechra Pharmaceuticals PLC (LON:DPH) has made a small bolt-on acquisition.
It is paying £4.4mln or 2.4-times revenues, for Caledonian Holdings, a New Zealand supplier to vets specialising in horses.
The deal will establish Dechra as a leading equine pharmaceutical supplier in both Australia and New Zealand, the company said.
"We are pleased to have acquired the trade and assets of Caledonian which will be integrated into our existing Australian and New Zealand businesses. This will enable Dechra to leverage its position in the ANZ equine market," said chief executive Ian Page.